SREBF1 and metabolic dysfunction-associated steatotic liver disease: A great deal of studies have demonstrated the aberrant expression of SREBP1 in multiple diseases, such as pancreatic cancer [27], diabetic nephropathy [28], non-alcoholic fatty liver disease [29] and so on.